
If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE:CYBN) is many trips ahead of you.
The Toronto-based company is studying derivatives of psilocybin and DMT and plans to file an investigational new drug application with the FDA during this quarter, CEO Doug Drysdale said Tuesday at the inaugural Benzinga Psychedelics Capital Conference.